Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models
KRAS‒PDEδ interaction is revealed as a promising target for suppressing the function of mutant KRAS. The bottleneck in clinical development of PDEδ inhibitors is the poor antitumor activity of known chemotypes. Here, we identified novel spiro-cyclic PDEδ inhibitors with potent antitumor activity bot...
Saved in:
Main Authors: | Long Chen (Author), Jing Zhang (Author), Xinjing Wang (Author), Yu Li (Author), Lu Zhou (Author), Xiongxiong Lu (Author), Guoqiang Dong (Author), Chunquan Sheng (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity
by: Jungeun Lee, et al.
Published: (2022) -
Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1
by: Jing Zhang, et al.
Published: (2022) -
Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo
by: Xinyuan Xu, et al.
Published: (2024) -
Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
by: Gülru Kayık, et al.
Published: (2017) -
Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
by: Yahui Huang, et al.
Published: (2020)